Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/9/2021 | Underperform → Market Perform | Raymond James | |
| 8/26/2021 | $6.00 → $6.50 | Underweight | Wells Fargo |
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) ("Prospect", "our", or "we") today announced that Morningstar DBRS ("DBRS") has reaffirmed Prospect's investment grade issuer and long term senior debt credit ratings at BBB(low), and assigned a revised trend of Stable. "We are very pleased that Morningstar DBRS, which has rated Prospect for many years, has reaffirmed our investment grade credit ratings," said Grier Eliasek, President and Chief Operating Officer at Prospect. "Our strong business profile is supported by a multi-decade track record, over $21 billion invested across 400+ investments, $4.7 billion in cumulative principal bond repayments
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) ("Prospect", "our", or "we") today announced the full and timely repayment of our convertible bond due March 2025, marking another milestone in Prospect's long-standing track record of responsible and low debt leverage balance sheet management. With this latest repayment, Prospect has now over our more than 20-year history repaid approximately $4.7 billion in principal bond obligations across 874 debt tranches spanning diversified funding sources, reinforcing Prospect's reputation as a reliable and disciplined issuer in the capital markets. Prospect's repaid bond obligations include institutional non-c
HONEY BROOK, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- R-V will be participating in several upcoming industry events. Ackley, Beta Star, Genesis, and R.W. Hartnett will be exhibitors at the Interphex trade show April 1-3 in New York City. Ackley and R.W. Hartnett will be exhibiting at the CPHI show October 28-30 in Frankfurt, Germany. Having four of its brands at the world's biggest pharma-centric trade shows demonstrates R-V's emergence as a significant player across the pharmaceutical landscape and is indicative of a company-wide commitment to manufacturing excellence, regardless of the industry. Market and product diversity has been a key differentiator of R-V Industries over its 51-year
4 - PROSPECT CAPITAL CORP (0001287032) (Issuer)
4 - PROSPECT CAPITAL CORP (0001287032) (Issuer)
4 - PROSPECT CAPITAL CORP (0001287032) (Issuer)
Raymond James upgraded Prospect Capital from Underperform to Market Perform
Wells Fargo reiterated coverage of Prospect Capital with a rating of Underweight and set a new price target of $6.50 from $6.00 previously
Wells Fargo reiterated coverage of Prospect Capital with a rating of Underweight and set a new price target of $6.00 from $5.75 previously
SC 13D/A - PROSPECT CAPITAL CORP (0001287032) (Subject)
SC 13D/A - PROSPECT CAPITAL CORP (0001287032) (Subject)
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. ("Priority Income Fund" or the "Fund") announced today that the Fund's Board of Directors has declared distributions on shares of the Fund's 7.00% Series D Term Preferred Stock due 2029 ("Series D"), 6.625% Series F Term Preferred Stock due 2027 ("Series F"), 6.000% Series H Term Preferred Stock due 2026 ("Series H"), 6.125% Series I Term Preferred Stock due 2028 ("Series I"), 6.000% Series J Term Preferred Stock due 2028 ("Series J"), 7.000% Series K Cumulative Preferred Stock ("Series K"), and 6.375% Series L Term Preferred Stock due 2029 ("Series L"). Ex-Dividend DateRecord DatePayable DateDistribution per ShareSer
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Priority Income Fund, Inc. ("Priority Income Fund" or the "Fund") announced today that it will redeem all outstanding shares of its 6.000% Series H Term Preferred Stock Due 2026 ((CUSIP: 74274W 798, NYSE:PRIF) (the "Series H Preferred Shares") at a price of $25 per Series H Preferred Share, plus accrued but unpaid dividends per Series H Preferred Share from March 31, 2025, to but excluding, the Redemption Date (the "Redemption Price"). The redemption date will be April 9, 2025 (the "Redemption Date"). On the Redemption Date, the Redemption Price will become due and payable on the Series H Preferred Shares and any dividends shall cease to accumu
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ:PSEC) (the "Company" or "Prospect") today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended December 31, 2024 on Monday, February 10, 2025. The Company also expects to issue its earnings press release on Monday, February 10, 2025, after the close of the markets. The Company will host a conference call on Tuesday, February 11, 2025 at 9:00 a.m. Eastern Time. The conference call dial-in number will be 888-338-7333. A recording of the conference call will be available for approximately 30 days. To hear a replay, call 8
4 - PROSPECT CAPITAL CORP (0001287032) (Issuer)
4 - PROSPECT CAPITAL CORP (0001287032) (Issuer)
4 - PROSPECT CAPITAL CORP (0001287032) (Issuer)
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman. This press release features multimedia. View the full release here: https:/
POS EX - PROSPECT CAPITAL CORP (0001287032) (Filer)
POS EX - PROSPECT CAPITAL CORP (0001287032) (Filer)
POS EX - PROSPECT CAPITAL CORP (0001287032) (Filer)